The company has completed phase III clinical trials and NDA registration and production of the tetravalent influenza virus subunit vaccine for children and adults developed using its own patented technology. This product, with its high purity and good safety, is more suitable for the vaccination of children and the elderly, and also marks that China's tetravalent influenza virus subunit vaccine is in the forefront of similar products in the world; Clinical trials of 23-valent pneumococcal polysaccharide vaccine were conducted. At the same time, the company continues to increase investment in research and development, and a number of viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines are being promoted simultaneously in the Shanghai/Taizhou R&D Center and pilot platform.

It is the founding principle of Zhonghui Biology to focus on international trends instead of simple replication, and create innovative vaccines. Caring for life, protecting health, and creating global technological innovation vaccines are the mission of Zhonghui Biology! Zhonghui Biology will carry forward the spirit of innovation, pragmatism, self-discipline, integrity, and always adhere to the struggle, so that China can use global innovative vaccines, and the world can use China's high-quality vaccines!

The first phase of the company covers an area of 70 mu, with a construction area of 50000 square meters. It has production workshops, central laboratories, animal rooms, research and development complex buildings, power centers, storage centers, and other supporting facilities that meet the requirements of national standards. Completed the construction of a GMP production line with international standards for influenza stock solution workshops and preparation workshops, and obtained the "Production License" and "Laboratory Animal Use License" for vaccines; In Phase II, an additional 80 mu of land will be used for industrialized production of all pipeline varieties. The company has been granted 10 invention patents and 5 national registered trademarks. He has been awarded honorary titles such as "Potential Unicorn Enterprise in Jiangsu High and New Technology Industrial Development Zone in 2020", "Private Science and Technology Enterprise in Jiangsu Province", and "Top Ten Industrial Transformation and Innovation Investment Projects in Taizhou City".

Currently, the company has a team of over 300 people, and its core team members are professionals from the production and research and development fields of biological products at home and abroad, with many years of experience in vaccine research and development, production, testing, and management. The company has received 1 "entrepreneurship and innovation talent" project in Jiangsu Province, 3 support items from the "113 talents" high-level innovative talent plan in Jiangsu Province, 1 support item from the high-level entrepreneurial talent plan, and 1 support item from the special contribution talent project.

"Not making simple replication, aiming at international trends, and making innovative vaccines are the founding principles of Zhonghui Biology. Caring for life and protecting health are the mission of Zhonghui Biology!"! Zhonghui Biology will carry forward the spirit of innovation, pragmatism, self-discipline, integrity, and always adhere to the struggle, and make unremitting efforts to let China use global innovative vaccines, and let the world use China's high-quality vaccines!